Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy

Molecular Therapy

Volumn 15, Issue 1, 2007, Pages 114-122

  Iankov, Ianko D ^a   Blechacz, Boris ^a   Liu, Chunsheng ^a   Schmeckpeper, Jeffrey D ^a   Tarara, James E ^a   Federspiel, Mark J ^a   Caplice, Noel ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD CELL; CANCER SURVIVAL; CANCER THERAPY; CELL FUSION; CELL TRANSFER; CONTROLLED STUDY; DISSEMINATED CANCER; ENDOTHELIUM CELL; EXPERIMENTAL NEOPLASM; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; LIVER CELL CARCINOMA; LYMPHOMA; MEASLES; MEASLES VIRUS; MONOCYTE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUS; OVARY CANCER; PASSIVE IMMUNIZATION; RAJI CELL; TUMOR XENOGRAFT; VIRION; VIRUS ATTENUATION; VIRUS IMMUNITY;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE THERAPY; HUMANS; INJECTIONS, INTRAVENOUS; MEASLES; MICE; MICE, SCID; MORBILLIVIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OVARIAN NEOPLASMS; SURVIVAL RATE; TRANSGENES; VIRUS INTERNALIZATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MEASLES VIRUS;

EID: 33846015067     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300020     Document Type: Article

References (45)

1. Lin, E and Nemunaitis, J (2004). Oncolytic viral therapies. Cancer Gene Ther 11: 643-664.
2. Nakamura, T and Russell, SJ (2004). Oncolytic measles viruses for cancer therapy. Expert Opin Biol Ther 4: 1685-1692.
3. Grote, D et al. (2001). Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97: 3746-3754.
4. Peng, KW, Ahmann, GJ, Pham, L, Greipp, PR, Cattaneo, R and Russell, SJ (2001). Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98: 2002-2007.
5. Peng, KW, TenEyck, CJ, Galanis, E, Kalli, KR, Hartmann, LC and Russell, SJ (2002). Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62: 4656-4662.
6. Phuong, LK et al. (2003). Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 63: 2462-2469.
7. Heinzerling, L, Kunzi, V, Oberholzer, PA, Kundig, T, Naim, H and Dummer, R (2005). Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106: 2287-2294.
8. Dingli, D et al. (2004). Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103: 1641-1646.
9. Griffin, D (2001). Measles virus In: Knipe DM and Howley PM (eds). Fields Virology. Lippincott Williams & Wilkins: Philadelphia, pp 1401-1441.
10. Morrison, TG (2003). Structure and function of a paramyxovirus fusion protein. Biochim Biophys Acta 1614: 73-84.
11. Dorig, RE, Marcil, A, Chopra, A and Richardson, CD (1993). The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75: 295-305.
12. Naniche, D et al. (1993). Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67: 6025-6032.
13. Tatsuo, H, Ono, N, Tanaka, K and Yanagi, Y (2000). SLAM (CDw150) is a cellular receptor for measles virus. Nature 406: 893-897.
14. Forthal, DN, Landucci, G, Habis, A, Zartarian, M, Katz, J and Tilles, JG (1994). Measles virus-specific functional antibody responses and viremia during acute measles. J Infect Dis 169: 1377-1380.
15. Bouche, FB, Ertl, OT and Muller, CP (2002). Neutralizing B cell response in measles. Viral Immunol 15: 451-471.
16. Malvoisin, E and Wild, F (1990). Contribution of measles virus fusion protein in protective immunity: Anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J Virol 64: 5160-5162.
17. Forthal, DN, Landucci, G, Katz, J and Tilles, JG (1993). Comparison of measles virus-specific antibodies with antibody-dependent cellular cytotoxicity and neutralizing functions. J Infect Dis 168: 1020-1023.
18. Forthal, DN and Landucci, G (1998). In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J Immunol Methods 220: 129-138.
19. Perrin, LH, Joseph, BS, Cooper, NR and Oldstone, MB (1976). Mechanism of injury of virus-infected cells by antiviral antibody and complement: participation of IgG, F(ab′)2, and the alternative complement pathway. J Exp Med 143: 1027-1041.
20. Permar, SR et al. (2003). Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 77: 4396-4400.
21. El Mubarak, HS et al. (2004). Measles virus protein-specific IgM, IgA, and IgG subclass responses during the acute and convalescent phase of infection. J Med Virol 72: 290-298.
22. Isa, MB et al. (2001). Measles virus-specific immunoglobulin G isotype immune response in early and late infections. J Clin Microbiol 39: 170-174.
23. Itoh, M, Okuno, Y and Hotta, H (2002). Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups. J Clin Microbiol 40: 1733-1738.
24. Toptygina, AP, Pukhalsky, AL and Alioshkin, VA (2005). Immunoglobulin G subclass profile of antimeasles response in vaccinated children and in adults with measles history. Clin Diagn Lab Immunol 12: 845-847.
25. Forthal, DN, Aarnaes, S, Blanding, J, de la Maza, L and Tilles, JG (1992). Degree and length of viremia in adults with measles. J Infect Dis 166: 421-424.
26. Devaux, P, Christiansen, D, Plumet, S and Gerlier, D (2004). Cell surface activation of the alternative complement pathway by the fusion protein of measles virus. J Gen Virol 85: 1665-1673.
27. Sissons, JG, Oldstone, MB and Schreiber, RD (1980). Antibody-independent activation of the alternative complement pathway by measles virus-infected cells. Proc Natl Acad Sci USA 77: 559-562.
28. Esolen, LM, Ward, BJ, Moench, TR and Griffin, DE (1993). Infection of monocytes during measles. J Infect Dis 168: 47-52.
29. Mrkic, B et al. (1998). Measles virus spread and pathogenesis in genetically modified mice. J Virol 72: 7420-7427.
30. Roscic-Mrkic, B et al. (2001). Roles of macrophages in measles virus infection of genetically modified mice. J Virol 75: 3343-3351.
31. Peng, KW et al. (2003). Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther 14: 1565-1577.
32. Permar, SR et al. (2004). Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis 190: 998-1005.
33. Cole, C et al. (2005). Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 11: 1073-1081.
34. Peng, KW et al. (2006). Pharmacokinetics of oncolytic measles virotherapy: Eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther 13: 732-738.
35. Komarova, S, Kawakami, Y, Stoff-Khalili, MA, Curiel, DT and Pereboeva, L (2006). Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 5: 755-766.
36. Confino, E, Harlow, L and Gleicher, N (1990). Peritoneal fluid and serum autoantibody levels in patients with endometriosis. Fertil Steril 53: 242-245.
37. Stallwood, Y, Fisher, KD, Gallimore, PH and Mautner, V (2000). Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients. Gene Ther 7: 637-643.
38. Dingli, D et al. (2005). Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun 337: 22-29.
39. Duprex, WP, McQuaid, S, Roscic-Mrkic, B, Cattaneo, R, McCallister, C and Rima, BK (2000). In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J Virol 74: 7972-7979.
40. Peng, KW, Facteau, S, Wegman, T, O'Kane, D and Russell, SJ (2002). Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 8: 527-531.
41. Rowe, HM et al. (2006). Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther 13: 310-319.
42. Giraudon, P and Wild, TF (1985). Correlation between epitopes on hemagglutinin of measles virus and biological activities: Passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity. Virology 144: 46-58.
43. Simper, D et al. (2003). Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of noncardiac origin are enriched in transplant atherosclerosis. Circulation 108: 143-149.
44. Iankov, ID, Pandey, M, Harvey, M, Griesmann, GE, Federspiel, MJ and Russell, SJ (2006). Immunoglobulin G antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 80: 8530-8540.
45. Firsching, R et al. (1999). Measles virus spread by cell-cell contacts: uncoupling of contact-mediated receptor (CD46) downregulation from virus uptake. J Virol 73: 5265-5273.